{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:22:23Z","timestamp":1783786943051,"version":"3.55.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metronomic oral cyclophosphamide (MOC) presents many potential advantages, such as significantly less severe side effects than standard regimens, ease of administration, and the delivery of a dose-dense but not necessarily dose-intense treatment. These observations prompted us to evaluate in a retrospective, multicenter study the efficacy and toxicity of MOC in a real-life series of pretreated cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study is a multicenter, retrospective analysis of the activity of single-agent MOC in patients with recurrent or residual epithelial ovarian, fallopian tube, or primary. Eligible patients were continuously treated with MOC at 50 mg\/day until progression, toxicity, or death. Overall response rate (ORR), stable disease (SD), and disease control rate (DCR) were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 62 patients. Three patients reached a complete response rate (5%), 11 had a partial response rate (18), and 15 had stabilization of disease (24) for an ORR of 23% and a DCR of 47%. Patients with low-grade indolent tumors showed an ORR and an SD rate higher than that observed in non-indolent ones (33% vs. 18% and 28% vs. 14%, respectively). Overall, progression-free survival was 3.5 months (range 1\u20139 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Single-agent MOC is active and very well tolerated in a significant fraction of patients with refractory, recurrent, or residual epithelial ovarian, fallopian tube, or primary peritoneal cancer. In the vision of a practical approach, single-agent MOC may be a useful palliative treatment option for patients with poor tolerance to high-dose regimens or widely pretreated. Further studies are needed better to characterize the role of such an approach in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231189867","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T02:58:17Z","timestamp":1690513097000},"page":"853-859","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8406-9416","authenticated-orcid":false,"given":"Vittorio","family":"Gebbia","sequence":"first","affiliation":[{"name":"Casa di Cura Torina, Palermo, Italy"},{"name":"Faculty of Medicine and Surgery, Kore University, Enna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-2914","authenticated-orcid":false,"given":"Federica","family":"Martorana","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Humanitas Istituto Clinico Catanese, Catania, Italy"},{"name":"Department of Clinical and Experimental Medicine, Center of Experimental Oncology and Hematology, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Scandurra","sequence":"additional","affiliation":[{"name":"Medical Oncology, Ospedale Cannizzaro, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Valerio","sequence":"additional","affiliation":[{"name":"Medical Oncology, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cufari","sequence":"additional","affiliation":[{"name":"Pharmacist Private Practice, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Humanitas Istituto Clinico Catanese, Catania, Italy"},{"name":"Department of Clinical and Experimental Medicine, Center of Experimental Oncology and Hematology, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vita","family":"San\u00f2","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Humanitas Istituto Clinico Catanese, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Scollo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, Kore University, Enna, Italy"},{"name":"Gynecological Oncology Unit, Ospedale Cannizzaro, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"bibr1-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2935"},{"key":"bibr2-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1369"},{"key":"bibr3-10781552231189867","unstructured":"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/metronomic-chemotherapy"},{"key":"bibr4-10781552231189867","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958003-00001"},{"key":"bibr5-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0181"},{"key":"bibr6-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103148"},{"key":"bibr7-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10399"},{"key":"bibr8-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9872"},{"key":"bibr9-10781552231189867","first-page":"427","volume":"7","author":"Gately S","year":"2001","journal-title":"Cancer J"},{"key":"bibr10-10781552231189867","first-page":"4342","volume":"63","author":"Bertolini F","year":"2003","journal-title":"Cancer Res"},{"key":"bibr11-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8"},{"key":"bibr12-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2565"},{"key":"bibr13-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.09.048"},{"key":"bibr14-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4880355"},{"key":"bibr15-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2019.07.006"},{"key":"bibr16-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900106"},{"key":"bibr17-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"bibr18-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"bibr19-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.11.1281"},{"key":"bibr20-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-947"},{"key":"bibr21-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12074"},{"key":"bibr22-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2017.04.006"},{"key":"bibr23-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100155"},{"key":"bibr24-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002467"},{"key":"bibr25-10781552231189867","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081954"},{"key":"bibr26-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3044"},{"key":"bibr27-10781552231189867","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10020056"},{"key":"bibr28-10781552231189867","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164710"},{"key":"bibr29-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6048"},{"key":"bibr30-10781552231189867","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.181627"},{"key":"bibr31-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5945"},{"key":"bibr32-10781552231189867","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.06.038"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231189867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231189867","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231189867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:51Z","timestamp":1777688931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231189867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1177\/10781552231189867"],"URL":"https:\/\/doi.org\/10.1177\/10781552231189867","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}